Description: This is a Phase I/II study of RAD001 (everolimus) for patients with glioblastoma or gliosarcoma (brain tumor). Patients are randomized to receive RAD 001 with the standard treatment of radiation plus temozolomide (oral chemotherapy) or to receive the standard treatment of radiation plus temozolomide alone.
This randomized phase II trial studies how well whole-brain radiation therapy (WBRT) with or without lapatinib ditosylate works in treating patients with breast cancer that has too many of a protein called human epidermal growth factor receptor 2 (HER2) on its cells and has spread to the brain. Radiation therapy uses high energy x rays to kill tumor cells. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy together with lapatinib ditosylate is an effective treatment for brain metastasis from breast cancer.
TH-302 is a drug that is inert unless activated by enzymes present under low oxygen condition. As many cancer types have low oxygen supply due to the rapid consumption by tumor cells, TH-302 is then broken down in these tumors to its active form which then can kill cancer cells. TH-302 will be administrated on days 1 and 15 with Bevacizumab in patients with recurrent high grade astrocytoma following progression with combined treatment with radiation and temozolomide and also after anti-angiogenic treatment.